US Dollar Slips After PCE Inflation Data Eases Fed Rate Hike Expectations 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Australian Household Spending Rebounds Strongly in May as Travel and Dining Drive Consumer Growth 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Oil Prices Drop as Strait of Hormuz Shipping Recovers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
Gold Prices Fall Below $4,000 as Strong Dollar, Fed Rate Hike Bets Weigh on Bullion 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
